8-K filing — Erasca, Inc. (ERAS)
Filed: 2026-10-16 AccNo: 0001193125-26-423433 Size: 149 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-16 AccNo: 0001193125-26-423433 Size: 149 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Grabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes.
Law firm Bernstein Liebhard announced an investigation into potential breaches of fiduciary duty by directors and officers of Embecta Corp. The firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. Current shareholders who purchased shares before November 25, 2025 are encouraged to contact the firm regarding their legal rights.